Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregabalin + celecoxib is a fixed-dose combination of two small molecule drugs used primarily for the management of pain, particularly in conditions involving both neuropathic and nociceptive mechanisms such as chronic low-back pain, acute postoperative pain, and lumbar disc herniation. Pregabalin is an anticonvulsant that binds to the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters like glutamate, norepinephrine, substance P, and dopamine. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces inflammation and pain by inhibiting prostaglandin synthesis. The combination has demonstrated superior analgesic efficacy compared to either drug alone and can reduce opioid requirements postoperatively with similar rates of adverse effects as monotherapy[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + celecoxib.